SHINE Technologies, a next-generation fusion company, will showcase FLARE™, the world's most powerful continuous fusion neutron system, at the IEEE Nuclear & Space Radiation Effects and at the Technology of Fusion Energy Meeting (TOFE). FLARE,...
Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases, announced that the first patient has been dosed in its...
Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, announced initiation of enrollment for its Phase 1 clinical study of CYT-108. A recombinant variant of the alpha-2-macroglobulin...
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or...
BioArctic AB's partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly lecanemab-irmb (U.S. brand name: Leqembi)...
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, recently received U.S. Food and Drug Administration clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram. This innovation means that plasma...
Tentarix Biotherapeutics announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and...
Kiromic BioPharma, Inc. reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic....
Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced that VIGPODER™ (vigabatrin) for oral solution, USP, a treatment for appropriate patients with...
Brainomix, the AI-powered medtech company, announces the publication of a new study in the prestigious peer-reviewed journal American Journal of Respiratory and Critical Care Medicine (AJRCCM)1, resulting from a research collaboration AstraZeneca,...
PLT Health Solutions, Inc. announced BioTRUST Nutrition® LLC, a leading eCommerce-based nutrition brand with a portfolio of high-quality, science-backed products focused on healthy aging and improving healthspan, has introduced a new product...
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced three poster presentations at the 2024...
Viscient Biosciences ("Viscient") announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a...
